Behavioral Economics and Self-Determination Theory to Change Diabetes Risk (BEST Change)
Status
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
Patients with prediabetes can significantly reduce their risk of developing type 2 diabetes mellitus (T2DM) by participating in a Diabetes Prevention Program (DPP) or using metformin, but very few patients with prediabetes engage in these strategies. This randomized controlled trial will compare, among adults with prediabetes, the effectiveness of financial incentives, tailored messages based on self-determination theory (SDT) principles, and the combination of financial incentives plus tailored messages based on SDT principles in decreasing hemoglobin A1c (HbA1c) and weight and in increasing participation in a DPP or use of metformin. Our main hypotheses are that the mean decrease in HbA1c will be greater in the arm that receives a combination of financial incentives plus tailored messages than in the arm that receives generic health education messages, and that the mean decrease in HbA1c will be greater in the arm that receives a combination of financial incentives plus tailored messages than in the arm that receives financial incentives alone and the arm that receives tailored messages alone. The study will also identify moderators and mediators of the effectiveness of the interventions and evaluate facilitators of and barriers to scalability, acceptability, and sustainability of the different interventions.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Primary Care Provider part of Michigan Medicine
- Body mass index (BMI) of 25 or higher (23 or higher if of Asian descent)
- Primary health insurance is U-M Premier Care
- Recent Hgb (hemoglobin) A1c 5.7 - 6.4% (inclusive)
Exclusion criteria
- Participated in pretesting of intervention materials
- Diagnosis of type 2 Diabetes Mellitus
- Serious mental health conditions (described by protocol)
- End stage renal disease (described by protocol)
- Alcohol dependence and opioid dependence (described by protocol)
- Unable to send and receive several text messages weekly
- No regular access to a smart phone or tablet with data capabilities or Wireless Fidelity (WiFi) connection at home
- Currently taking metformin
- Unable to take metformin due to contraindications or side effects
- Participated in a Diabetes Prevention Program covered by University of Michigan Premier Care insurance
- Currently enrolled in an interventional research study that is examining how a diet, program, or drug might: promote physical exercise, healthy eating habits, or weight loss; lower blood pressure; or lower blood sugar
- Not planning to live in local area over the next year
- Pregnant or planning a pregnancy in the next year
- Received treatment for an eating disorder (e.g. anorexia or bulimia), not including binge-eating disorder, in last 12 months
- Intensive cancer treatment such as bone marrow transplant, chemotherapy, radiation, or cancer related surgery (not including hormonal chemotherapy like Tamoxifen) in last six months or near future
- Organ transplant in last six months
- Bariatric/ gastric bypass surgery, gastric sleeve surgery, or gastric balloon procedure in last six months
- Stroke, heart attack, heart surgery, or hospitalization for congestive heart failure in the past three months
- Other serious health issues or personal concerns that could prevent participant from completing study
Trial design
Primary purpose
Allocation
Interventional model
Masking
380 participants in 4 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal